GVK to work with Gates Foundation-funded neglected disease group

By Gareth Macdonald

- Last updated on GMT

Related tags Clinical trial Gvk Gvk biosciences

Indian CRO GVK Biosciences has been named as a preferred provider by a consortium, Product Development Partners (PDP), which is focused on drugs for neglected diseases.

Under the collaboration GVK will provide clinical support, logistics, monitoring and project management for trials PDP, a group not-for-profit entities part funded by the Bill and Melinda Gates foundation, is conducting in India and Bangladesh.

Illnesses on PDP’s target list include tuberculosis, malaria, HIV, pneumonia and diarrhoea which, despite affecting millions of people, are often overlooked by drug companies in favour of conditions that can generate higher revenues.

In return for its research efforts Hyderabad-headquartered GVK will receive a fee but only at a concessional rate according to senior vice president of clinical development Shoibal Mukherjee

Dr Mukherjee told Outsoucing-pharma.com that the contract research organisation (CRO) has considerable experience conducting clinical research in this field, which will be important to the success of the project.

GVK Biosciences has been working in the area of neglected diseases for several years, and it is this experience that puts the company in a position to participate in the Global Health Product Development Partners Consortium.

Mukherjee explained that GVK has been involved in the management and monitoring of six clinical trials with roughly a third of its clinical research workforce directly or indirectly associated with these projects.

He added that, although the work is progressing “clinical development of medicines is a lengthy and arduous process. It is typically 2 to 6 years before drugs in clinical trials become marketable and sometimes it is longer.

Related news

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us


View more